| Attributes | Values |
|---|
| rdf:type
| |
| Description
| - Anorexia nervosa (AN) je závažné a potenciálně život ohrožující psychiatrické onemocnění.Snažili jsme se zjistit,zda existuje positivní vliv na tělesnou hmotnost a BMI u pacientek s AN léčených kvůli depresi nebo úzkosti pomocí mirtazapinu.Metody:S použitím výzkumného plánu případů a kontrol (case–control design) jsme vyhledali 9 pacientek s AN léčené mirtazapinem kvůli depresi nebo anxiety v průběhu jejich hospitalizace. Vyhledali jsme také 9 kontrolních pacientek s AN bez farmakoterapie.Obě skupiny byly párovány vzhledem k věku a BMI. Skupiny případů a kontrol se na počátku nelišily významně věkem (15.2 1.9 vs. 14.7 1.7 let; p = 0.549), nebo BMI (15.6 2.3 vs. 15.6 2.1; p = 0.946).Hmotnost a BMI byly zjišťovány na začátku a znovu, když pacientky dokončily 1, 2, 3 a 4 týdny léčby. Výsledky: Průměrná dávka mirtazapinu na konci 4. týdne byla 21.7 1.8 mg. Pomocí analýzy rozptylu s opakovanými měřeními jsme nezjistili žádné významné rozdíly mezi případy a kontrolami vzhledem k hmotnosti (p = 0.98... (cs)
- Anorexia nervosa (AN) is a serious and potentially life-threatening psychiatric disorder.Pharmacotherapeutic possibilities still remain limited. We sought to determine if there was a positive effect on body weight and BMI in AN patients being treated for depression or anxiety with mirtazapine. Methods:Using a case–control design, we found 9 female patients with AN who had been treated with mirtazapine for depression or anxiety during hospitalization.We also found 9 female controls with AN without pharmacotherapy.The two groups of patients were matched according to age and BMI. Case and control groups did not differ significantly in age (15.2 1.9 Vs. 14.7 1.7 years; P = 0.549), or in BMI (15.6 2.3 Vs. 15.6 2.1; P = 0.946) at baseline.Weight and BMI were evaluated at baseline and again after the patients had completed 1, 2, 3 and 4 weeks of treatment.Results: The mean dose of mirtazapine was 21.7 1.8 mg at the end of week 4.Using ANOVA Repeated Measures,we found no significant differences betwee...
- Anorexia nervosa (AN) is a serious and potentially life-threatening psychiatric disorder.Pharmacotherapeutic possibilities still remain limited. We sought to determine if there was a positive effect on body weight and BMI in AN patients being treated for depression or anxiety with mirtazapine. Methods:Using a case–control design, we found 9 female patients with AN who had been treated with mirtazapine for depression or anxiety during hospitalization.We also found 9 female controls with AN without pharmacotherapy.The two groups of patients were matched according to age and BMI. Case and control groups did not differ significantly in age (15.2 1.9 Vs. 14.7 1.7 years; P = 0.549), or in BMI (15.6 2.3 Vs. 15.6 2.1; P = 0.946) at baseline.Weight and BMI were evaluated at baseline and again after the patients had completed 1, 2, 3 and 4 weeks of treatment.Results: The mean dose of mirtazapine was 21.7 1.8 mg at the end of week 4.Using ANOVA Repeated Measures,we found no significant differences betwee... (en)
|
| Title
| - Mirtazapine in the treatment of adolescent anorexia nervosa. Case-control study
- Mirtazapine in the treatment of adolescent anorexia nervosa. Case-control study (en)
- Mirtazapine v léčbě mentální anorexie u adolescentů. Studie případů a kontrol (cs)
|
| skos:prefLabel
| - Mirtazapine in the treatment of adolescent anorexia nervosa. Case-control study
- Mirtazapine in the treatment of adolescent anorexia nervosa. Case-control study (en)
- Mirtazapine v léčbě mentální anorexie u adolescentů. Studie případů a kontrol (cs)
|
| skos:notation
| - RIV/68081740:_____/08:00325598!RIV09-AV0-68081740
|
| http://linked.open...avai/riv/aktivita
| |
| http://linked.open...avai/riv/aktivity
| - Z(AV0Z70250504), Z(MSM0021620849)
|
| http://linked.open...iv/cisloPeriodika
| |
| http://linked.open...vai/riv/dodaniDat
| |
| http://linked.open...aciTvurceVysledku
| |
| http://linked.open.../riv/druhVysledku
| |
| http://linked.open...iv/duvernostUdaju
| |
| http://linked.open...titaPredkladatele
| |
| http://linked.open...dnocenehoVysledku
| |
| http://linked.open...ai/riv/idVysledku
| - RIV/68081740:_____/08:00325598
|
| http://linked.open...riv/jazykVysledku
| |
| http://linked.open.../riv/klicovaSlova
| - anorexia nervosa; treatment; antidepressants (en)
|
| http://linked.open.../riv/klicoveSlovo
| |
| http://linked.open...odStatuVydavatele
| - DE - Spolková republika Německo
|
| http://linked.open...ontrolniKodProRIV
| |
| http://linked.open...i/riv/nazevZdroje
| - European Child & Adolescent Psychiatry
|
| http://linked.open...in/vavai/riv/obor
| |
| http://linked.open...ichTvurcuVysledku
| |
| http://linked.open...cetTvurcuVysledku
| |
| http://linked.open...UplatneniVysledku
| |
| http://linked.open...v/svazekPeriodika
| |
| http://linked.open...iv/tvurceVysledku
| - Urbánek, Tomáš
- Hrdlička, M.
- Beranová, I.
- Zámečníková, R.
|
| http://linked.open...ain/vavai/riv/wos
| |
| http://linked.open...n/vavai/riv/zamer
| |
| issn
| |
| number of pages
| |
| is http://linked.open...avai/riv/vysledek
of | |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)